Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 24;15(11):1383-1389.
doi: 10.5306/wjco.v15.i11.1383.

Role of immunotherapy in gastric cancer with liver metastasis

Bogdan Gafton  1   2 , Stefan Morarasu  3 , Gabriel Dimofte  4
Affiliations
Editorial

Role of immunotherapy in gastric cancer with liver metastasis

Bogdan Gafton et al. World J Clin Oncol. .

Abstract

Gastric cancer continues to be a significant issue for public health, marked by its widespread occurrence and high mortality rates, even as the incidence of the disease shows a declining trend. The liver is the primary site for metastatic spread, with the peritoneum, lungs, and bones also being common targets. With the advent of biologic treatments and the introduction of immunotherapy for patients with metastatic conditions, the options to treat metastatic gastric cancer have expanded. This diversified therapeutic approach is designed to enhance patient quality of life and prolong survival, showcasing the progress in treatment modalities for individuals with gastric cancer and liver metastases.

Keywords: Gastric cancer; Immunotherapy; Liver metastases; Metastatic gastric cancer; Oncology; Surgical oncology.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
Overview of immunotherapy results in the main clinical trials. CPS: Combined positive score; DFS: Disease-free survival; FDA: Food and Drug Administration; OS: Overall survival; PFS: Progression-free survival.
See this image and copyright information in PMC

References

    1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14:26–38. - PMC - PubMed
    1. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40. - PMC - PubMed
    1. Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, Takahashi I, Ishigami S, Tsuji A, Higashi H, Nakamura T, Saeki H, Shirabe K, Kakeji Y, Sakai K, Baba H, Nishimaki T, Natsugoe S, Maehara Y Kyushu Study Group of Clinical Cancer. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302) Gastric Cancer. 2016;19:968–976. - PubMed
    1. Shasha T, Gruijs M, van Egmond M. Mechanisms of colorectal liver metastasis development. Cell Mol Life Sci. 2022;79:607. - PMC - PubMed
    1. Wu K, Zhang G, Shen C, Zhu L, Yu C, Sartorius K, Ding W, Jiang Y, Lu Y. Role of T cells in liver metastasis. Cell Death Dis. 2024;15:341. - PMC - PubMed

Publication types

LinkOut - more resources